Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Corticosteroids Clear all

Conditions: Ovarian Cancer Recurrent
Interventions: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone; Genetic · Drug
Lead sponsor: Vector Y Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more

Conditions: Status Asthmaticus
Interventions: Montelukast Oral Granules, Albuterol, Corticosteroid; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma
Interventions: fluticasone; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 69 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: San Diego, California • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Prostate Cancer
Interventions: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more

Conditions: Pemphigus
Interventions: Sirolimus (formerly known as Rapamycin); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Cyclosporine, Sirolimus, Tacrolimus; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 20 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions: Infliximab + Prednisone, Methylprednisolone + Prednisone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more

Conditions: Asthma
Interventions: Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 7,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: White Plains, New York

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis
Interventions: Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Lateral Epicondylitis, Tennis Elbow
Interventions: extracorporeal shock wave therapy, Kenalog (triamcinolone), lidocaine 1% (lidocaine HCl 20mg); Procedure · Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION; Drug
Lead sponsor: Tampa Bay Uveitis Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions: Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 1 Year to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 2
States / cities: Bethesda, Maryland • Amarillo, Texas

Conditions: Acute Lymphoblastic Leukemia
Interventions: Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more

Conditions: COPD
Interventions: Low Dose Corticosteroids, High Dose Corticosteroids; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Plainsboro, New Jersey

Conditions: Asthma
Interventions: Placebo, BI 54903, Fluticasone propionate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more

Conditions: Heart Transplantation
Interventions: Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more

Search by objective public record fields.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Treating Exacerbations of Asthma With Oral Montelukast in Children

MethaCholine Bronchoprovocation Study (MeCIS)

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Impact of Tiotropium Add-on Therapy in Patients With Asthma

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia

ALL Adult Consortium Trial: Adult ALL Trial

Dose of Corticosteroids in COPD

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma